Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Major Radiation Dose De-Escalation Concurrent With Chemotherapy for HPV Associated Oropharyngeal Carcinoma
NCT03323463Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2017
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial in human papillomavirus-mediated oropharyngeal carcinoma (HPV+OPC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Effectiveness of study treatment at 2 years. Started Oct 2017; status: active, not recruiting.
02
Conditions
human papillomavirus-mediated oropharyngeal carcinoma (HPV+OPC)
Beyond the preview
Go deeper on NCT03323463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03323463.